why choose us

First received: April 18, 2023

Clinical Trial: Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors

Study Status: Completed

Recruit Status: RECRUITING

Condition: Non Small Cell Lung Cancer

Study Type: INTERVENTIONAL


Official Title: A Phase 1/2, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of TNG260 as Single Agent and in Combination With an Anti-PD-1 Antibody In Patients With STK11 Mu

Brief Summary: The goal of this interventional clinical trial is to learn about TNG260, a CoREST inhibitor, in combination with pembrolizumab in patients with advanced solid tumors with a known STK11 mutation.The main question[s] it aims to answer are:the recommended dose for Phase 2to evaluate the safety and tolerability of the combination therapyto determine the pharmacokinetics of TNG260to evaluate the initial antineoplastic activityParticipants will receive study treatment until they experience an undesirable side effect,…

Read more